版本:
中国

BRIEF-Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102

March 23 Aeglea Bio Therapeutics Inc

* Aeglea Biotherapeutics to present topline data from phase 1 trial of AEB1102 for treatment of Arginase I deficiency at 2017 ACMG annual clinical genetics meeting

* Treatment with AEB1102 well tolerated, no related adverse events or clinically significant abnormal laboratory results reported

* Study showed that single, intermittent doses of AEB1102 resulted in reduction of arginine in blood to normal levels Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐